The historical rank and industry rank for BrightPath Biotherapeutics Co's EV-to-FCF or its related term are showing as below:
TSE:4594'
s EV-to-FCF Range Over the Past 10 Years
Min: -21.15 Med: -3.3 Max: -0.3
Current: -3.3
During the past 12 years, the highest EV-to-FCF of BrightPath Biotherapeutics Co was -0.30. The lowest was -21.15. And the median was -3.30.
TSE:4594's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs TSE:4594: -3.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BrightPath Biotherapeutics Co (TSE:4594) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BrightPath Biotherapeutics Co's PE Ratio (TTM) for today is calculated as:
BrightPath Biotherapeutics Co's share price for today is 円50.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BrightPath Biotherapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-11.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BrightPath Biotherapeutics Co EV-to-FCF Related Terms
BrightPath Biotherapeutics Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4594 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, BrightPath Biotherapeutics Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrightPath Biotherapeutics Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BrightPath Biotherapeutics Co's EV-to-FCF falls into.
BrightPath Biotherapeutics Co's current Enterprise Value is 円4,788.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BrightPath Biotherapeutics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円-1,366.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co (TSE:4594) has a EV-to-FCF of -3.50 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BrightPath Biotherapeutics Co and its competitors. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #999999 out of 330 companies in the Biotechnology industry.
Is BrightPath Biotherapeutics Co's EV-to-FCF too high?
BrightPath Biotherapeutics Co's current EV-to-FCF is -3.50. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #999999 out of 330 companies for EV-to-FCF. This places BrightPath Biotherapeutics Co in the lower half of its industry. The industry median EV-to-FCF is 16.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BrightPath Biotherapeutics Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrightPath Biotherapeutics Co's current EV-to-FCF is -3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co (TSE:4594) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.64, compared to a current price of 円50.00 — trading 977.6% above its estimated fair value. The current EV-to-FCF is -3.50. BrightPath Biotherapeutics Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current EV-to-FCF is -3.50 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued.
The current stock price of 円50.00 is trading 977.6% above its estimated GF Value™ of 円4.64.
GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.
Key valuation signals for TSE:4594:
EV-to-FCF: -3.50
GF Value™: 円4.64 vs. price of 円50.00 (977.6% above fair value)
No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrightPath Biotherapeutics Co Business Description
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
46GF Score
Get the complete analysis for TSE:4594
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4594 has been successfully added to your 
